Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    BAY94-9027 | Hemophilia A
Previous Study | Return to List | Next Study

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01580293
Recruitment Status : Active, not recruiting
First Posted : April 19, 2012
Results First Posted : December 6, 2018
Last Update Posted : June 18, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

Haemophilia A is an inherited disorder in which one of the proteins, Factor VIII, needed to form blood clots is missing or not present in sufficient levels. In a person with haemophilia A, the clotting process is slowed and the person experiences bleeds that can result in serious problems and potential disability.

The current standard treatment for severe haemophilia A is regularly scheduled infusion of FVIII to keep levels high enough to prevent bleeding. Due to the short half-life of FVIII, prophylaxis may require treatment as often as every other day.

In this trial safety and efficacy of a long-acting recombinant factor VIII molecule is evaluated in subjects with severe Hemophilia A.

120-140 patients will receive open label treatment with long-acting rFVIII either on-demand to treat bleeds or prophylactically for 36 weeks in the main trial plus an optional extension to continue treatment for at least 100 total exposure days (ED). Patients on prophylactic treatment will receive study drug at dosing intervals between once and twice a week depending on their observed bleeding. Patients will attend the treatment centre for routine blood samples and be required to keep an electronic diary.

Male patients aged 12-65, with severe hemophilia A, previously treated with FVIII for at least 50 exposure days may be eligible for this study.


Condition or disease Intervention/treatment Phase
Hemophilia A Biological: BAY94-9027 Phase 2 Phase 3

Detailed Description:

Subjects in prophylactic treatment arms will undergo clinical evaluation at 10 weeks. Those with adequate control of bleeding will undergo randomization to every 5 or 7 day infusion. Those with continued bleeding will remain in treatment arm and have an increase in dose.

Part B-major surgery - optional sub study included to collect information on efficacy of BAY94-9027 in major surgical setting. Due to rarity of surgery in this population, enrollment to this sub-study may be independent of participation in main study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A
Actual Study Start Date : April 23, 2012
Actual Primary Completion Date : June 13, 2014
Estimated Study Completion Date : November 8, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: Arm 1
On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
Biological: BAY94-9027
Intravenous infusion of BAY94-9027

Experimental: Arm 2
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
Biological: BAY94-9027
Intravenous infusion of BAY94-9027

Experimental: Arm 3
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
Biological: BAY94-9027
Intravenous infusion of BAY94-9027

Experimental: Arm 4
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
Biological: BAY94-9027
Intravenous infusion of BAY94-9027




Primary Outcome Measures :
  1. Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial [ Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A ]
    Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds. A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the annualized bleeding rate (ABR).


Secondary Outcome Measures :
  1. Annualized Number of Joint Bleeds, Trauma, Spontaneous Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A [ Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A ]
    A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the ABR.

  2. Annualized Number of Total Bleeds in On-demand Treatment Arm and in Each Prophylaxis Arm, Part A, Extension [ Time Frame: at least 100 total exposure days acquired, Median (range) time in extension: 464 days (45-700) ]
    Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds.

  3. Number of Participants Developed Human Coagulation Factor VIII (FVIII) Inhibitor - Part A [ Time Frame: Weeks 0 to 36 during Part A ]
    FVIII inhibitor testing was done according to the Nijmegen modified Bethesda assay. A positive inhibitor test was defined with a threshold of ≥0.6 Bethesda unit (BU) at the central laboratory.

  4. Number of Bleeds Requiring 1, 2 or >= 3 Infusions to Control the Bleed - Part A [ Time Frame: Weeks 0 to 36 ]
    Number of bleeds requiring 1, 2 or >= 3 infusions to control the bleeding

  5. Number of Bleeds According to Locations - Part A [ Time Frame: Weeks 0 -36 ]
    Bleed locations were categorised as joint, muscle, skin/mucosa, internal, others and missing.

  6. Number of Bleeds Over Time Since Previous Prophylaxis Infusion - Part A [ Time Frame: Weeks 0 to 36 ]
  7. Number of Bleeds According to Participant's Assessment of Response to Treatment - Part A [ Time Frame: Weeks 0 to 36 during Part A ]
    Response to treatment was assessed by participant as excellent, good, moderate, poor or missing during Part A of the study.

  8. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Total Dose Per Kilogram Per Year - Part A [ Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A ]
    For prophylaxis patients, the dose is related to all infusions.

  9. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion - Part A [ Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A ]
    For prophylaxis patients, the dose per infusion related to prophylaxis infusion.

  10. Number of Participants Requiring an Increase in Dose Frequency, or Dose Increase, During Weeks 10 to 36 - Part A [ Time Frame: Weeks 10 to 36 during Part A ]
  11. Number of Surgeries According to Physician's Assessment of Adequacy of Hemostasis in Major Surgery - Part B [ Time Frame: Day of surgery ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Adequacy of hemostasis was assessed as excellent, good, moderate or poor, by the surgeon or interventionalist during Part B of the study.

  12. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion for Major Surgery - Part B [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Total dose per kilogram per Infusion was expressed in international units per kilogram per infusion (IU/kg/infusion).

  13. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions for Major Surgery - Part B [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.rFVIII usage expressed as number of infusions and IU/kg per year, as well as IU/kg per event (surgery) was assessed by investigator.

  14. Maximum Drug Plasma Concentration (Cmax) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A [ Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours ]
    Cmax: Maximum observed drug concentration following an infusion of 60 IU/kg

  15. Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A [ Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours ]
    AUC: The total area under the plasma concentration versus time curve following an infusion of 60 IU/kg .

  16. Terminal Elimination Half Life (t1/2) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A [ Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours ]
    t1/2: Terminal half-life is the time the plasma concentration during terminal phase is halved following an infusion of 60 IU/kg .

  17. Overall Human Coagulation Factor VIII (FVIII) Recovery Value by Chromogenic Assay - Part A [ Time Frame: Weeks 0 to 36 during Part A ]
    Recovery was calculated by the following formula: Recovery = (post-infusion FVIII activity - pre-infusion FVIII activity ) * weight / dose (in IU). Recovery is the increase of FVIII activity after the injection normalized by dose: IU/dl per IU/kg = kg/dL

  18. Change From Baseline in Quality of Life by Hemophilia Specific Quality of Life Instrument or Questionnaire for Adults (Haemo-QoL-A) Overall Score at Week 36 - Part A [ Time Frame: Week 0 (baseline) and Week 36 during Part A ]
    Quality of life (QoL) was measured by the Haemo-QoL-A overall score, which ranged from 0 (the worst condition) to 100 (the best condition).


Other Outcome Measures:
  1. Change From Baseline in Overall Pain Severity and Interference Due to Pain at Week 36 - Part A [ Time Frame: Week 0 (baseline) and Week 36 during Part A ]
    Brief Pain Inventory (BPI) - Short Form (BPI-SF) was a 15-item, self-administered, validated tool developed to assess pain used in the study for patient reported outcomes. Scores ranged from 0 to 10 and a higher score indicates a higher level of pain/interference.

  2. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 36 - Part A [ Time Frame: Week 0 (baseline) and Week 36 during Part A ]
    The WPAI is a validated instrument to assess the effect of hemophilia on ability to work, attend classes, and perform regular daily activities in participants aged 12 and above. The WPAI also contained classroom impairment questions (CIQ). The questionnaire was self-administered and comprised of nine questions that elicited information on work, classroom, and daily activity impairment during the previous seven days. WPAI outcomes that are overall work and activity impairment, transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

  3. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions- Part A [ Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A ]
    For prophylaxis patients, the dose is related to all infusions.

  4. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram With Prophylaxis Treatment - Part A [ Time Frame: Weeks 10 - 36 during Part A ]
    For prophylaxis patients, the dose per kilogram is related to prophylaxis infusions.

  5. Number of Minor Surgeries According to Physician's Assessment of Adequacy of Hemostasis - Part A [ Time Frame: Weeks 0 to 36 during Part A ]
    Minor surgery was defined as any surgical procedure that did not meet the definition of major, and included simple dental extractions, incision and drainage of abscesses, or simple excisions.

  6. Number of Surgeries According to Physician's Assessment of Response to Hemostasis, Post-surgery - Part B Main Trial [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Response to treatment during surgery was assessed by investigator/surgeon as excellent, good, moderate, poor or missing during Part B of the study.

  7. Number of Participants With Change/Drop in Hemoglobin/Hematocrit Laboratory Assessments - Part B [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Hematocrit is defined as the volume percentage (%) of red blood cells in blood.

  8. Maximum Blood Loss During Major Surgery - Part B [ Time Frame: day of surgery ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.

  9. Number of Participants Who Took Anti-fibrinolytic Medications During Major Surgery - Part B [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.

  10. Volume of Blood Transfused in Major Surgery - Part B [ Time Frame: Up to 3 weeks post-surgery during Part B ]
    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male; 12-65 years of age
  • Subjects with severe hemophilia A
  • Previously treated with factor VIII for a minimum of 150 exposure days

Exclusion Criteria:

  • Inhibitors to FVIII (current evidence or history)
  • Any other inherited or acquired bleeding disorder in addition to Hemophilia A
  • Platelet count < 100,000/mm3
  • Creatinine > 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) > 5x upper limit of normal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580293


  Show 59 Study Locations
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01580293     History of Changes
Other Study ID Numbers: 13024
2011-005210-11 ( EudraCT Number )
First Posted: April 19, 2012    Key Record Dates
Results First Posted: December 6, 2018
Last Update Posted: June 18, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Bayer:
Hemophilia A, factor VIII, prophylaxis

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants